Press

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Talis Biomedical Corporation (TLIS) on Behalf of Investors

Retrieved on: 
Monday, December 13, 2021
Real estate investment trust, Person, FDA, Associated Press, Company, Insurance, Press, Industry, Bloomberg Businessweek, COVID-19, Financial Times, Information technology, The Wall Street Journal, NASDAQ, SEC, CEO, DOJ, Investment, SCAS, Program, GLOBE, News, Publication, GPM, Animal, Pharmaceutical industry, Forbes, Reuters

LOS ANGELES, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (Talis or the Company) (NASDAQ: TLIS ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • LOS ANGELES, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, continues its investigation on behalf of Talis Biomedical Corporation (Talis or the Company) (NASDAQ: TLIS ) investors concerning the Companys possible violations of the federal securities laws.
  • Then, on August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer, Brian Coe, had stepped down.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Talkspace, Inc. (TALK, TALKW) on Behalf of Investors

Retrieved on: 
Thursday, December 16, 2021
Legal, Professional Services, Real estate investment trust, Person, FDA, Associated Press, Company, Insurance, Press, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, NASDAQ, SEC, CEO, DOJ, SCAS, Program, News, Publication, GPM, Security (finance), Pharmaceutical industry, Talkspace, Forbes, Reuters

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Talkspaces stock fell $1.23, or 36%, to close at $2.16 per share on November 16, 2021, thereby injuring investors.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Everbridge, Inc. (EVBG) on Behalf of Investors

Retrieved on: 
Thursday, December 16, 2021
Legal, Professional Services, Real estate investment trust, Person, Uncertainty, Everbridge, FDA, Associated Press, Insurance, Press, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, NASDAQ, SEC, DOJ, SCAS, Program, Bloomberg, News, Publication, GPM, Pharmaceutical industry, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Everbridge, Inc. (Everbridge or the Company) (NASDAQ: EVBG ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Everbridge, Inc. (Everbridge or the Company) (NASDAQ: EVBG ) investors concerning the Companys possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Everbridges stock fell $52.37, or 45%, to close at $63 per share on December 10, 2021, thereby injuring investors.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sleep Number Corporation (SNBR) on Behalf of Investors

Retrieved on: 
Thursday, December 16, 2021
Legal, Professional Services, Storm, Real estate investment trust, Person, FDA, February 13–17, 2021 North American winter storm, Associated Press, Company, Insurance, Press, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, NASDAQ, SEC, DOJ, SCAS, Program, Sleep Number, News, Publication, GPM, Pharmaceutical industry, Animal, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sleep Number Corporation (Sleep Number or the Company) (NASDAQ: SNBR ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sleep Number Corporation (Sleep Number or the Company) (NASDAQ: SNBR ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Sleep Numbers stock fell $14.80, or 12%, to close at $110.13 per share on April 22, 2021, thereby injuring investors.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Organogenesis Holdings Inc. (ORGO) on Behalf of Investors

Retrieved on: 
Thursday, December 16, 2021
Legal, Professional Services, Real estate investment trust, Person, FDA, Associated Press, Company, Insurance, Press, Federation, Organogenesis, Medicare, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, LLP, NASDAQ, SEC, DOJ, Investment, SCAS, Program, News, Publication, GPM, Security (finance), Pharmaceutical industry, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Organogenesis Holdings Inc. (Organogenesis or the Company) (NASDAQ: ORGO ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Organogenesis Holdings Inc. (Organogenesis or the Company) (NASDAQ: ORGO ) investors concerning the Companys possible violations of the federal securities laws.
  • On October 12, 2021, an anonymous report was published on Value Investors Club, a website for investors to share ideas.
  • The report alleged that Organogenesis has been improperly billing the federal government for $250 million annually.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tecnoglass Inc. (TGLS) on Behalf of Investors

Retrieved on: 
Wednesday, December 15, 2021
Legal, Professional Services, Real estate investment trust, Person, Hindenburg, FDA, Associated Press, Insurance, Press, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, LLP, Review, NASDAQ, TGLS, SEC, DOJ, SCAS, Program, News, Hindenburg Research, Publication, GPM, Security (finance), Pharmaceutical industry, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tecnoglass Inc. (Tecnoglass or the Company) (NASDAQ: TGLS ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tecnoglass Inc. (Tecnoglass or the Company) (NASDAQ: TGLS ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Tecnoglass stock fell $12.14, or 36%, to close at $21.56 per share on December 9, 2021, thereby injuring investors.
  • Whistleblower Notice: Persons with non-public information regarding Tecnoglass should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cloopen Group Holding Limited (RAAS) on Behalf of Investors

Retrieved on: 
Tuesday, December 14, 2021
Legal, Professional Services, Real estate investment trust, Person, Solution, FDA, Associated Press, ADS, Insurance, Decision-making, Press, IPO, NYSE, Industry, Bloomberg Businessweek, Publication, Information technology, Financial Times, The Wall Street Journal, SEC, American depositary receipt, Annual report, DOJ, SCAS, Program, News, RAAS, GPM, Pharmaceutical industry, Animal, Security (finance), Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cloopen Group Holding Limited (Cloopen or the Company) (NYSE: RAAS ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cloopen Group Holding Limited (Cloopen or the Company) (NYSE: RAAS ) investors concerning the Companys possible violations of the federal securities laws.
  • In February 2021, Cloopen conducted its initial public offering (IPO), selling 23 million American Depositary Shares (ADSs or shares) at $16 per ADS.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors

Retrieved on: 
Tuesday, December 14, 2021
Legal, Professional Services, Real estate investment trust, Therapy, Person, Food, BLA, FDA, Associated Press, Insurance, Biologics license application, Press, Industry, Bloomberg Businessweek, Information technology, Financial Times, The Wall Street Journal, Freedom, NASDAQ, Review, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Freedom of Information Act (United States), DOJ, SCAS, Program, News, Publication, GPM, Medical device, Pharmaceutical industry, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Revances stock fell $6.85, or 25%, to close at $20.45 per share on October 12, 2021, thereby injuring investors.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England Biolabs - Forecast to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Infectious Diseases, Health, Genetics, Science, Research, Mosaic, Integration, Agriculture, Associated Press, Bacteria, European Medical Association, Huntington's disease, Intellia Therapeutics, Press, Cell, Infection, Lists of diseases, CRSP, Genome, Gene editing, Human, ZFN, World, Integrated DNA Technologies, Chicago (franchise), Immortalised cell line, COVID-19, Cancer, Fungus, Nature, Cas9, HIV, Parasitism, Intention, Genetic engineering, Research, Biotechnology, Association, Growth, World Health Organization, Disease, DNA, WHO, Genome editing, TALEN, University, NTLA, Food, Virus, National Baptist Convention, USA, Inc., GenScript Biotech, Genetic code, Technology, Vaccine, Antibiotics, Medical device, CRISPR, New England Biolabs, CRISPR, EU

The "Gene Editing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Editing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the gene editing market are CRISPR, GenScript USA Inc., Horizon Discovery Group plc, Integrated DNA Technologies and New England Biolabs.
  • The gene editing market consists of sales of gene editing technology such as CRISPR/CAS9, zinc finger nucleus, and talens and related services.
  • The gene editing market covered in this report is segmented by technology into CRISPR, TALEN, ZFN.

Wolters Kluwer Triumphs with Five 2021 Best in Biz Awards

Retrieved on: 
Monday, December 13, 2021
Professional Services, Technology, Finance, Software, Consulting, Banking, Online, Solution, Software as a service, Wolters Kluwer, Optum, Associated Press, GRC, ADP, AEX, Press, Intelligence, Fidelity, CASH, Environment, FRR, Compliance, Risk, General manager, Silver, USA Today, Leadership, Efficiency, Enterprise Products, Information services, Risk management, Wolters, Accounting, Health, Publication, Financial adviser, Bank, Biz

Wolters Kluwer Compliance Solutions has earned five 2021 Best in Biz Awards for product excellence.

Key Points: 
  • Wolters Kluwer Compliance Solutions has earned five 2021 Best in Biz Awards for product excellence.
  • The wins include two Gold-level awards for OneSumX ProViso, as Best New Product of the Year, and CASH Suite, for Product Line of the Year.
  • Combining these accolades with another solution win, Wolters Kluwer earned an additional distinction, finishing in second place as Best in Biz Awards Most Awarded Companies in 2021, competing against major companies such as ADP, Optum and Fidelity.
  • The divisions legal solutions businesses are Wolters Kluwer CT Corporation and Wolters Kluwer ELM Solutions .